The FTSE 100 opened in the red on Tuesday morning, as the shortened final day of trading for the year kicked off with some trepidation.Stocks in New York struggled on Monday, trade in Asian equities was unconvincing, and the nerves fed through to Europe on New Year's Eve.The FTSE 100 index opened down 8.35 points, 0.1%, at 8,112.66. It is up 5.0% for the year.The FTSE 250 was up just 9.64 points a

Stock prices edged lower in London early Monday, as investors assessed the latest economic data from China, and considered possible trajectories for US interest rate cuts.The FTSE 100 index opened down 7.26 points, 0.1%, at 7,704.45. The FTSE 250 was down 3.03 points at 19,188.90, and the AIM All-Share was down 1.05 points, 0.1%, at 757.73.The Cboe UK 100 was slightly lower at 771.49, the Cboe UK

London?s FTSE 100 made a tepid start to 2024, with underwhelming manufacturing data from the UK and eurozone doing little to lift sentiment.Equities in New York are called to open lower ahead of a key week for the US interest rate outlook. The latest Federal Reserve meeting minutes are released on Wednesday, before the official US jobs report on Friday.The FTSE 100 index was down 29.34 points, 0.4

Investors have been betting that the end is in sight for the cycle of interest rate hikes, with higher risk growth stocks gradually coming back into favour. But you don't need to be cavalier with your investing approach, there is still excellent value to be found among growth stocks.Most readers are unlikely to know WAG Payment Solutions (WPS) yet this is a FTSE 250 company expected to grow revenu

A healthy number of lesser-known businesses have done very well in share price terms since coming to market in the last two years, with price appreciation reflecting strong operational performances or the fact they sate voracious investor appetite for a particular theme.Readers will be familiar with high-profile post-pandemic newcomers on the London Stock Exchange (LSGE) trading above their issue

Despite the UK being a world leader in the life sciences sector it can be difficult to find London-listed companies which operate in this space compared with biotech or drug development specialists.Investing via funds is an easier way to get exposure, particularly as you can access companies in the UK and overseas. We'll talk you through some examples later in this article.Life sciences can be app